Inclusion Criteria:

- Patients with clinical stage T1-T4 carcinoma of the prostate

- Must have undergone radical radiation and at least 2 years of Pharmacological
androgen ablation.Pharmacological androgen ablation may include: LHRH-agonists with
or without Non-steroidal androgen ablation, Steroidal Anti-androgens, Progestational
agents, and Cypoterone (Androcur).

- Must be currently 6 months or more after their last injection of LHRH-agonists if it
was being given every 3 months or 4 months or more after their last injection, if it
was being given monthly. If the patient was on oral androgen ablation agent, they
must be off this medication for a period of at least 4 months.

- currently off hormonal therapy

- Able to sign the consent form and fill out questionnaire used in the study.

Exclusion Criteria:

- No patients who have been treated, or are currently being treated with Bicalutamide

- no previous orchidectomy.